Sana will increase its investment in its type 1 diabetes program ... transplant rejection in type 1 diabetes is active; Sana expects to share proof of concept data in 2024 and/or 2025.

These studies show the "diabetic pancreas is not incapable of expressing insulin" and the proof-of-concept experiments "address unmet medical needs in type 1 diabetes." The advances in the ...

These studies show the "diabetic pancreas is not incapable of expressing insulin" and the proof-of-concept experiments "address unmet medical needs in type 1 diabetes". The advances in the ...

“This successful NHP study provides proof of concept for an upcoming clinical trial using allogeneic, HIP-edited primary islets in patients with type 1 diabetes.” UIC team spurs fresh hope for ...

Patients with type 1 diabetes (T1D) who have risk factors such ... “Metformin should definitely be included in the concept,” he said, though it is not suitable for long-term use due to the ...

"This early proof of concept is encouraging and may lead ... project for developing a minimally invasive therapeutic for type 1 diabetes." Diabetes mellitus is a chronic heterogeneous metabolic ...

But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can’t make enough of their own ...

Sana will increase its investment in its type 1 diabetes program with the cash savings from these changes. “Early clinical data with our hypoimmune platform (HIP) suggest HIP-modified cells ...